Imunon, Inc. (NASDAQ:IMNN – Get Free Report) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totalling 341,600 shares, an increase of 7.6% from the June 15th total of 317,500 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average daily volume of 45,900 shares, the days-to-cover ratio is presently 7.4 days.
Analyst Ratings Changes
Separately, HC Wainwright reduced their price target on shares of Imunon from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, May 14th.
Get Our Latest Report on Imunon
Imunon Stock Down 1.0 %
Imunon (NASDAQ:IMNN – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05. Equities analysts predict that Imunon will post -2.09 earnings per share for the current fiscal year.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Recommended Stories
- Five stocks we like better than Imunon
- What is the Nikkei 225 index?
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- 10 Best Airline Stocks to Buy
- Parabolic Rise of This Stock Shows No Signs of Slowing
- Using the MarketBeat Stock Split Calculator
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.